124 related articles for article (PubMed ID: 9216692)
1. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
Meden H; Wittkop Y; Kuhn W
Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
[TBL] [Abstract][Full Text] [Related]
2. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
3. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Spieth K; Kaufmann R; Gille J
Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan as an effective second-line therapy in ovarian cancer.
Gropp M; Meier W; Hepp H
Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan in the treatment of metastatic renal cell carcinoma.
Rigos D; Wechsel HW; Bichler KH
Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
[TBL] [Abstract][Full Text] [Related]
6. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study.
Breitbach GP; Meden H; Schmid H; Kühn W; Sass G; Schach S; Schmidt-Rohde P; Bastert G;
Anticancer Res; 2002; 22(5):2923-32. PubMed ID: 12530019
[TBL] [Abstract][Full Text] [Related]
9. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
[TBL] [Abstract][Full Text] [Related]
10. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
11. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
13. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
14. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
[TBL] [Abstract][Full Text] [Related]
15. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer.
Mougenot P; Fabbro M; Bressolle F; Pouessel D; Culine S; Pinguet F
Oncol Rep; 2006 Jan; 15(1):237-41. PubMed ID: 16328062
[TBL] [Abstract][Full Text] [Related]
17. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
18. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy.
Moosavi AS; Gilani MM; Tehranian A; Esfahani JK
J Obstet Gynaecol; 2004 Apr; 24(3):292-3. PubMed ID: 15203631
[TBL] [Abstract][Full Text] [Related]
19. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
20. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
